You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Unique Antimicrobial Catheter to Prevent Urinary Tract Infections

    SBC: NORTHWEST MEDIA, INC            Topic: NICHD

    DESCRIPTION (provided by applicant): In this Phase I we will develop and evaluate the first unit of an online serious game for foster and primary parents of neglected children. The goal of the training is to learn how parents in these two historically compartmentalized roles can improve their parenting by working cooperatively. Research shows that cross-training strategies can optimize the chances ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Automated genome-phenome analysis

    SBC: SimulConsult, Inc.            Topic: NHGRI

    DESCRIPTION (provided by applicant): Automated genome-phenome analysis The declining cost of whole exome sequencing (WES) is nearing the point at which the spread of WES into clinical practice will be limited largely by the cost of interpreting the resultsand comparing the to the patient's clinical findings. This project tests the feasibility of reducing this interpretaton cost by pairing aut ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. High Pressure Sample Preparation Instrumentation for DNA Sequencing.

    SBC: PRESSURE BIOSCIENCES, INC.            Topic: NHGRI

    DESCRIPTION (provided by applicant): Encouraged by NIH's challenge to enable the 1000 genome, current developments in massively parallel sequencing (MPS) continue to increase throughput and reduce the cost of whole-genome sequencing. Unfortunately, the corresponding sample preparation methodologies now lag behind in throughput and DNA quality, thus slowing the pace of discovery and adoption ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A Bifunctional Katp Channel Activator and Redox Mimetic for BPD

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Radikal Therapeutics is developing a novel small molecule therapy (R-801) for neonatal prematurity that triggers an endogenous cytoprotective defense and thereby blocks pulmonary inflammation and acute lung injury (ALI). R-801 is formed from the covalent fusion of 2 moieties with demonstrated tissue protective properties: 1) a mito-K+-ATP channel activating do ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Hybrid Katp Channel Opener and Redox Catalyst for Lung Transplantation

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel cytoprotective agent (R-801) for the prevention of ischemia-reperfusion injury (IRI) following lung transplantation (LTX). In rodent models of severe redox injury, R-801profoundly reduces organ dysfunction, tissue infarction, and parenchymal inflammation. R- 801 is formed from the covalent fusion of 2 distinct m ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. System for Targeted Estimation of Physiologic States to Facilitate SCAMPs in Inte

    SBC: Etiometry Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Sterling Point Research (SPR), in collaboration with Children's Hospital Boston (CHB), is proposing to develop a System for Targeted Estimation of Physiologic States (STEPS) that will enable the use of Standardized Clinical Assessment and Management Plans (SCAMPs) in the Intensive Care Unit. SCAMPs are a methodology for the systematic optimization of treat ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. A Wearable Balance Booster- Stepping Closer to the Market

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): High volume mechanical ventilation (MV) induces a lethal pulmonary complication, termed ventilator induced lung injury (VILI), via the generation of toxic free radical and oxidant species that damage the alveolocapillary membrane, trigger pro-inflammatory gene expression, and induce pulmonary arterial hypertension and respiratory failure. To address this unm ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Decoy Peptides: Development of a Novel Therapeutic for Metastatic Cancer

    SBC: New England Research Institutes, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): There are two components to this study where human subjects are involved: development of content, and assessment of content. For the Development and Reel Review three focus groups will be held: 1) general audience; 2) minority, 3) parents specifically. We will conduct groups in these three categories to ensure we produce a film that is generally appealing, but ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. DFG-out inhibitors of Abl-kinases to treat PML

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a novel pharmaceutical therapy for prematurity that targets a developmental deficiency in thioredoxin (Trx), a protein that serves as a central regulator of cellular reductant status. Trx is expressed t levels in the fetal lung too low to adequately counter the redox stress of extrauterine life, and i thus relatively def ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. An Automated Platform for High-throughput Network Electrophysiology

    SBC: CALISTA THERAPEUTICS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government